Date Title  
May 28, 2019
Summary ToggleSol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo
 
May 23, 2019
Summary ToggleSol-Gel to Present at Upcoming Healthcare Investor Conferences in June
 
May 22, 2019
Summary ToggleSol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update
 
Apr 18, 2019
Summary ToggleSol-Gel Technologies Announces Participation in Upcoming Investor Conference
 
Apr 15, 2019
Summary ToggleSol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris
 
Mar 21, 2019
Summary ToggleSol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
 
Feb 06, 2019
Summary ToggleSol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%
 
Jan 15, 2019
Summary ToggleSol-Gel Technologies Appoints John Vieira as U.S. Head of Commercialization
 
Dec 17, 2018
Summary ToggleSol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
 
Dec 04, 2018
Summary ToggleSol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo
 
Displaying 31 - 40 of 58 results